Piramal Pharma : Q1 2024 Financial Quarterly Report : YoY Sales Up 11.57 %, QoQ Down 23.56 %

The comprehensive analytics outlining the performance and outlook of Piramal Pharma Limited”s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Today, we’re looking at Piramal Pharma Limited’s financial performance for the Q1(Jun 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 11.57 %. However, it did see a marginal slip of -23.56 % from the previous quarter. Expenses decreased slightly by -13.64 % quarter-on-quarter, aligning with the annual rise of 8.05 %. Operating profit, while up 54.54 % compared to last year, faced a quarter-on-quarter dip of -61.41 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 2.91 %, but a shrinkage of -10.28 % sequentially. Other income rose by 147.34 % compared to the last quarter, despite an annual decline of -62.93 %. Interest expenses dropped significantly by -6.36 % from the previous quarter, yet the year-over-year decrease remains at a moderate -9.75 %. Depreciation costs fell by -5.9 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 6.3 %. Profit before tax grew annually by 37 % but saw a reduction from the preceding quarter by -129.66 %.
Tax expenses as a percentage of profits decreased slightly by -57.54 % compared to last year, with a more notable quarter-on-quarter decrease of -123.13 %. Net profit rose by 10.08 % year-on-year but witnessed a -187.53 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 19.28 % but a quarterly fall of -187.01 %. In summary, Piramal Pharma Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

In reviewing Piramal Pharma Limited’s 2024(Q1) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 11.57 % year-on-year growth, although there was a slight dip of -23.56 % from the previous quarter. Expenses rose by 8.05 % compared to the previous year, with a decrease of -13.64 % quarter-on-quarter. Operating Profit surged by 54.54 % annually, and saw a -61.41 % decrease from the last quarter.
Net Profit showed yearly increase of 10.08 %, and experienced a -187.53 % decrease from the previous quarter. Earnings Per Share (EPS) rose by 19.28 % annually, however dipped by -187.01 % compared to the last quarter. In essence, while Piramal Pharma Limited exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.